In a consecutive series of 146 kidney transplant recipients treated with cyclosporin A a strong correlation between matching for the HLA-A, HLA-B, and HLA-DR loci specificities and outcome of the grafts was observed in male recipients with non-O blood groups. Such a beneficial effect of matching was not found in female patients or male patients with blood group 0. In these patients survival of the grafts at one year was good irrespective of the number of HLA-A, B, and DR mismatches. Also in 47 male heart transplant recipients immune responsiveness against mismatched HLA antigens was related to blood group. A significantly higher incidence of rejection episodes was observed in male patients with non-O blood groups (n=32) than in those with blood group 0 (n= 15). Matching for HLA-DR reduced the number of acute rejection episodes in male patients with non-0 blood.
Introduction
In 1977 Opelz and Terasaki showed that male patients with non-O blood groups who had been given kidney grafts poorly matched for HLA-A and B loci specificities were at high risk of graft failure.' Though this difference in immune responsiveness was confirmed,2 most follow up analyses of patients with transplants failed to take this interaction into account. To some extent this omission may be explained by the introduction of cyclosporin A,' which seemed to overshadow the importance of HLA matching by improving graft survival, especially in recipients of poorly matched grafts.4 Nevertheless, we wondered whether the influence of blood group, sex, and HLA matching was still relevant in the cyclosporin era.
Selection of donors and recipients of renal allografts is based on HLA matching, so that these recipients are a biased group with respect to the proportion with well matched and poorly matched grafts. By contrast, in heart transplantation selection of donors and recipients is not based on HLA matching. Furthermore, routine serial endomyocardial biopsy specimens are taken frequently during the first postoperative year, so that we know the exact number of acute rejection episodes. (table III) . By contrast, two or more rejection episodes occurred in 16 out of 28 nonblood-group 0 male recipients of an HLA-DR mismatched graft. No significant difference was recorded in the incidence of rejection episodes between recipients of heart grafts with one HLA-DR mismatch (n= 17) and those with two HLA-DR mismatches (n= 11). In the group with one HLA-DR mismatch 10 patients were treated for two or more rejection episodes and in the group with two HLA-DR mismatches six were so treated. 2 We emphasise, however, that all our patients were treated with cyclosporin, whereas patients in the quoted reports were treated with azathioprine. Thus even with cyclosporin male patients with non-O blood groups given poorly matched (HLA-A, B, and DR) kidney grafts retain strong immune responsiveness against mismatched HLA antigens. Screening for leucocytotoxic anti-HLA antibodies in our patients showed that only a minority of the male patients with non-O blood (3%; data not shown) belonged to the so called highly immunised group.'0 Our male patients apparently did not not mount a strong humoral immune response against transfused mismatched HLA antigens. Goulmy et al showed that compatibility for the HLA-B locus specificities in male patients predisposed to immune nonreactivity and good graft prognosis." In our study 23 out of 45 male patients with non-O blood were given kidney grafts with two to four HLA-A and B mismatches. Only two turned out to be compatible for the HLA-B locus specificities. This may explain the poor graft prognosis in these patients (50% graft survival at one year; table I).
Recently Eurotransplant and other organ exchange organisations-for example, the United Kingdom Transplant Service-have switched emphasis from HLA-A and B matching to HLA-DR matching in selecting donors and recipients. HLA-DR matching not only improves renal allograft prognosis'2'6 but also reduces the number of acute rejection episodes,'7"8 resulting in better graft function.'7 '9 In our series of renal transplant recipients a strongly beneficial effect of HLA-DR matching was found only in male patients with non-O blood.
In heart transplantation the incidence and severity of rejection episodes may play an important part in long term graft function and survival. Thus identifying high immune responders is important. Our finding of a BMJ VOLUME 297 8 OCTOBER 1988 D-strong correlation between the incidence of acute cardiac allograft rejection and ABO blood group in male recipients precisely identifies such patients with high immune responsiveness. As heart transplant recipients with blood group 0 always receive ABO identical grafts, our observations may explain the findings of McKenzie et al,20 who observed a highly significant incidence of graft failure due to rejection in ABO incompatible donor-recipient pairs-that is, patients with non-O blood types. As our pretransplantation transfusion policy is the same for heart transplant recipients with type 0 and non-type 0 blood, it is unlikely that the low incidence of acute rejection episodes recorded in patients with type 0 blood was due to a quantitative transfusion effect.2 The low immune responsiveness against cardiac allograft antigens in these patients is also illustrated by the fact that their single acute rejection episodes were easily reversed with methylprednisolone in all cases, in contrast with the non-O group (only half the cases).
Matching for HLA-A and B loci specificities improved cardiac allograft prognosis. 
